The 14 most recent market catalysts affecting $AVBP, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 12, 2026
Corporate Catalyst
Neutral
Impact 55
Analysts Update Ratings and Price Targets for ArriVent BioPharma
On November 11, 2026, several prominent Wall Street analysts, including those from Citi and Oppenheimer, reiterated their 'buy' ratings for ArriVent BioPharma (AVBP). This collecti…
Nov 11, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Raises Price Target for ArriVent BioPharma
Truist Securities, a prominent financial institution, updated its research on ArriVent BioPharma, a clinical-stage biopharmaceutical company. The firm reiterated its 'Buy' rating a…
Nov 9, 2026
Corporate Catalyst
Neutral
Impact 65
ArriVent BioPharma Reports Third Quarter 2026 Financial Results
ArriVent BioPharma's 8-K filing details its third-quarter 2026 financial results, showing a healthy cash balance of $393.2 million, which provides a runway through mid-2028. This f…
Oct 28, 2026
Corporate Catalyst
Bullish
Impact 75
Guggenheim Raises ArriVent BioPharma Price Target to $30.00
Guggenheim, a prominent financial institution, has raised its price target for ArriVent BioPharma (AVBP) from $18 to $30. This substantial increase, reported on October 27, 2026, s…
Oct 25, 2026
Corporate Catalyst
Bullish
Impact 65
ArriVent BioPharma Announces Initial Phase 1 Results for ARR-217 in Gastrointestinal Cancers
ArriVent BioPharma announced encouraging initial Phase 1 results for ARR-217, an antibody-drug conjugate for gastrointestinal cancers. This is significant because positive early-st…
Oct 24, 2026
Corporate Catalyst
Neutral
Impact 65
ArriVent BioPharma to Present Phase 1 Data for ARR-217 at ESMO Congress 2026
ArriVent BioPharma announced it will present initial Phase 1 data for its ADC candidate, ARR-217, at the ESMO Congress in October 2026. This is a significant event for the company …
Oct 19, 2026
Corporate Catalyst
Neutral
Impact 75
ArriVent Publishes FURTHER Phase 1b Results Of Firmonertinib In Cancer Cell
The publication of further positive Phase 1b results for Firmonertinib is a significant corporate catalyst for ArriVent. Positive clinical trial data, especially in oncology, can d…
Oct 6, 2026
Corporate Catalyst
Bearish
Impact 95
ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low
ArriVent BioPharma announced that its Phase 3 FURVENT trial for firmonertinib, a lung cancer drug, failed to achieve its primary endpoint of progression-free survival. This is a ma…
Oct 6, 2026
Corporate Catalyst
Bearish
Impact 95
ArriVent BioPharma shares are trading lower after the company announced its Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion-mutant NSCLC failed to meet its primary endpoint of progression-free survival.
This headline represents a major corporate catalyst for ArriVent BioPharma. The failure of a Phase 3 trial for a lead drug candidate, especially in a first-line indication, is a si…
Oct 6, 2026
Macro/Central Bank
Bullish
Impact 65
Dow Jumps 200 Points; US Trade Deficit Widens In August
The core event is the widening U.S. trade deficit, which reached a record high due to increased imports. This indicates strong domestic demand but could also signal potential econo…
Aug 17, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Raises Price Target to $47
HC Wainwright & Co. analyst Robert Burns has maintained a 'Buy' rating on ArriVent BioPharma (AVBP) and raised the price target from $44 to $47. This action signals continued analy…
Aug 13, 2026
Corporate Catalyst
Neutral
Impact 55
Guggenheim Reiterates Buy on ArriVent BioPharma, Maintains $45 Price Target
Guggenheim analyst Michael Schmitz has reaffirmed a 'Buy' rating and a $45 price target for ArriVent BioPharma. This action signals that the analyst's positive outlook on the compa…
Aug 12, 2026
Corporate Catalyst
Bearish
Impact 92
ArriVent BioPharma Q2 EPS $(1.05) Misses $(0.99) Estimate
ArriVent BioPharma (AVBP) reported a Q2 EPS of $(1.05), missing the consensus estimate of $(0.99) and representing a 16.67% increase in losses year-over-year. This earnings miss is…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.